Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

Academic Article

Publication Date:

2018

Short description:

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? / Pouillon, L., Van Stappen, J., Bossuyt, P., Danese, S., Peyrin-Biroulet, L.. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY. - ISSN 1521-6918. - 32-33:(2018), pp. 17-25. [10.1016/j.bpg.2018.05.006]

Iris type:

1.1 Articolo in rivista

List of contributors:

Pouillon, L; Van Stappen, J; Bossuyt, P; Danese, S; Peyrin-Biroulet, L

Authors of the University:

DANESE SILVIO

Handle:

https://iris.unisr.it/handle/20.500.11768/119951

Published in:

BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY

Journal